Biblio
Natural compounds and mesenchymal stem cells: implications for inflammatory-impaired tissue regeneration. Stem Cell Res Ther. 2024;15(1):34.
. Patients with chronic myeloid leukemia and coronavirus disease 2019 in the Omicron era. Ann Hematol. 2023.
. Population Pharmacokinetics and Pharmacogenetics Analyses of Dasatinib in Chinese Patients with Chronic Myeloid Leukemia. Pharm Res. 2023.
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation. Cancer Chemother Pharmacol. 2023.
Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. Br J Haematol. 2018.
. . A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Adv. 2020;4(22):5846-5857.
A seven-color panel including CD34 and TdT could be applied in >97% patients with T cell lymphoblastic leukemia for minimal residual disease detection independent of the initial phenotype. Leuk Res. 2018;72:12-19.
Sodium Tanshinone IIA Sulfonate Enhances the BMP9-BMPR2-Smad1/5/9 Signaling Pathway in Rat Pulmonary Microvascular Endothelial Cells and Human Embryonic Stem Cell-derived Endothelial Cells. Biochem Pharmacol. 2022:114986.
Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study. Chin Med J (Engl). 2022;135(19):2344-2350.
. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database. Clin Exp Med. 2024;24(1):35.
. The transcription factor ZEB2 drives the formation of age-associated B cells. Science. 2024;383(6681):413-421.
Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia. Hematol Oncol. 2024;42(2):e3264.
Validation of the imatinib-therapy failure model. Leukemia. 2023.
.